Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.62 |
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | CRHBP | P24387 | 2/20 | 0.62 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.62 |
| ▸ | HTT | P42858 | 2/20 | 0.62 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.56 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.56 |
| ▸ | ITGAL | P20701 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | OXTR | P30559 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | MAOA | P21397 | 2/20 | 0.39 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3705883 | 0.90 | SMN1; SMN2 (0.57) | SMN1; SMN2LMNACRHBPCRHR2HTT | |
| SCHEMBL4424800 | 0.89 | SMN1; SMN2 (0.74) | SMN1; SMN2LMNACRHBPCRHR2HTT | |
| SCHEMBL7567158 | 0.89 | SMN1; SMN2 (0.74) | SMN1; SMN2LMNACRHBPCRHR2HTT | |
| SCHEMBL7565783 | 0.89 | SMN1; SMN2 (0.74) | SMN1; SMN2LMNACRHBPCRHR2HTT | |
| SCHEMBL19680565 | 0.86 | LMNA (0.63) | SMN1; SMN2LMNACRHBPCRHR2HTT | |
| SCHEMBL10861876 | 0.84 | SMN1; SMN2 (0.48) | SMN1; SMN2LMNACRHBPCRHR2HTT | |
| Dioxane SCHEMBL27667743 | 0.83 | SMN1; SMN2 (0.52) | SMN1; SMN2LMNACRHBPCRHR2HTT | |
| SCHEMBL35655 | 0.82 | SMN1; SMN2 (0.63) | SMN1; SMN2LMNACRHBPCRHR2HTT | |
| SCHEMBL10170816 | 0.80 | OXTR (0.52) | SMN1; SMN2LMNACRHBPCRHR2HTT | |
| SCHEMBL346944 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110234641-B | Germination promoter | 先正达参股股份有限公司 | 2022-10-14 | — | — | CN | disclosed |
| US-11434472-B2 | Agent for removing undifferentiated iPS cells | Sumitomo Pharma Co., Ltd. (JP) | 2022-09-06 | — | — | US | disclosed |
| CN-109072178-B | Haploid inducer compositions and methods of use thereof | 先正达参股股份有限公司 | 2022-08-02 | — | — | CN | disclosed |
| US-20220127281-A1 | HETEROARYL COMPOUNDS THAT INHIBIT G12C MUTANT RAS PROTEINS | ASTRAZENECA UK LIMITED (GB) | 2022-04-28 | — | — | US | disclosed |
| EP-3450433-B1 | PURINE DERIVATIVES AS TLR7 INHIBITORS FOR TREATING E.G. SYSTEMIC LUPUS ERYTHEMATOSUS | SUMITOMO DAINIPPON PHARMA CO LTD (JP) | 2021-08-18 | — | — | EP | disclosed |
| CN-109414019-B | Plant growth regulator compounds | 先正达参股股份有限公司 | 2021-04-30 | — | — | CN | disclosed |
| CN-107207440-B | 2-oxo-3, 4-dihydroquinoline compounds as plant growth regulators | 先正达参股股份有限公司 | 2020-11-10 | — | — | CN | disclosed |
| US-20200268728-A1 | DRUG TARGETING CANCER STEM CELL | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2020-08-27 | — | — | US | disclosed |
| US-10703755-B2 | Substituted purine derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2020-07-07 | — | — | US | disclosed |
| US-20200109153-A1 | HETEROARYL COMPOUNDS THAT INHIBIT G12C MUTANT RAS PROTEINS | ASTRAZENECA AB (SE) | 2020-04-09 | — | — | US | disclosed |
| US-20040053826-A1 | Uses of polypeptides | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-03-18 | — | — | US | disclosed |
| US-20030207863-A1 | Preventives and remedies for central nervous system diseases | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-11-06 | — | — | US | disclosed |
| EP-1331010-A1 | PREVENTIVES AND REMEDIES FOR CENTRAL NERVOUS SYSTEM DISEASES | Takeda Chemical Industries, Ltd. (JP) | 2003-07-30 | — | — | EP | disclosed |
| EP-1310490-A1 | GPR14 ANTAGONIST | Takeda Chemical Industries, Ltd. (JP) | 2003-05-14 | — | — | EP | disclosed |
| EP-1308513-A1 | USE OF POLYPEPTIDE | Takeda Chemical Industries, Ltd. (JP) | 2003-05-07 | — | — | EP | disclosed |
| US-6534496-B1 | Prophylactic and/or therapeutic drug for obesity and obesity associated diseasestor diabetes with a reduced risk for central side effects and high universality in usage. Another object of the a lipolytic agent, or a prophylactic and/or | TAKEDA CHEMICAL INDUSTRIES, INC. (JP) | 2003-03-18 | — | — | US | disclosed |
| US-20020177593-A1 | Agents and crystals for improving excretory potency of urinary bladder | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2002-11-28 | — | — | US | disclosed |
| US-6319916-B1 | CHOLINESTERASE INHIBITOR FOR SENILE DEMENTIA AND ALZHEIMER'S TREATMENT | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-11-20 | — | — | US | disclosed |
| EP-1118322-A1 | DRUGS FOR IMPROVING VESICAL EXCRETORY STRENGTH | Takeda Chemical Industries, Ltd. (JP) | 2001-07-25 | — | — | EP | disclosed |
| EP-0567090-A2 | Benzoxazepine derivatives as cholinesterase inhibitors | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-10-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200109153-A1 | HETEROARYL COMPOUNDS THAT INHIBIT G12C MUTANT RAS PROTEINS | KRAS, NRAS, HRAS | SMN1; SMN2 1691/4885LMNA 2364/4885CRHBP 3797/4885 |
| US-20220127281-A1 | HETEROARYL COMPOUNDS THAT INHIBIT G12C MUTANT RAS PROTEINS | KRAS, NRAS, HRAS | SMN1; SMN2 1617/4885LMNA 2320/4885CRHBP 3799/4885 |
| US-20020177593-A1 | Agents and crystals for improving excretory potency of urinary bladder | ACHE, BPHL, BCHE | SMN1; SMN2 2689/4885LMNA 3299/4885CRHBP 4339/4885 |
| US-11434472-B2 | Agent for removing undifferentiated iPS cells | SALL4, NR4A2, NES | SMN1; SMN2 2230/4885LMNA 2989/4885CRHBP 3596/4885 |
| US-20040053826-A1 | Uses of polypeptides | NPSR1, SCTR, GRPR | SMN1; SMN2 3147/4885LMNA 3551/4885CRHBP 107/4885 |
| US-20030207863-A1 | Preventives and remedies for central nervous system diseases | UTS2R, PRSS12, CTSA | SMN1; SMN2 90/4885LMNA 1884/4885CRHBP 667/4885 |
| US-20200268728-A1 | DRUG TARGETING CANCER STEM CELL | NR5A1, NR3C1, NR3C2 | SMN1; SMN2 3102/4885LMNA 3942/4885CRHBP 3581/4885 |
| US-10703755-B2 | Substituted purine derivative | TLR7, TLR9, TLR1 | SMN1; SMN2 967/4885LMNA 1693/4885CRHBP 3515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.